REPORT ID 17948

Global IBS-C Drugs Market Size, Status and Forecast 2022

Publish Date
03-Oct-17
Pages
118
Format
Electronic (PDF)

This report studies the global IBS-C Drugs market, analyzes and researches the IBS-C Drugs development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like
    Catalent Pharmaceuticals Solutions
    Nestle
    Abbott Laboratories
    Synergy Pharmaceuticals
    Sucampo Pharmaceuticals
    Novartis Pharma Ag
    Astellas Pharmaceuticals
    Ardelyx, Inc
    Synthetic Biologics, Inc
    Teva Pharmaceutical Industries
    Bama-Geve, SLU
    Ferring BV
    Ironwood Pharmaceuticals, Inc
    Salix Pharmaceuticals Ltd
    Norgine B.V
    Prometheus Laboratories Inc
    Actavis Nordic A/S
    Albireo Pharma Inc
    Yuhan Corp
    Astrazeneca Plc
    The Menarini Group
    Ono Pharmaceutical Co., Ltd

Market segment by Regions/Countries, this report covers
    United States
    EU
    Japan
    China
    India
    Southeast Asia

Market segment by Type, IBS-C Drugs can be split into
    Linaclotide
    Lubiprostone
    Osmotic Laxatives
    Stimulant Laxatives
    Other

Market segment by Application, IBS-C Drugs can be split into
    Hospital Pharmacies
    Retail Pharmacies
    Online Pharmacies

If you have any special requirements, please let us know and we will offer you the report as you want.


 
			   
Table of Contents

Global IBS-C Drugs Market Size, Status and Forecast 2022
1 Industry Overview of IBS-C Drugs
    1.1  IBS-C Drugs Market Overview
        1.1.1 IBS-C Drugs Product Scope
        1.1.2 Market Status and Outlook
    1.2 Global IBS-C Drugs Market Size and Analysis by Regions
        1.2.1 United States
        1.2.2 EU
        1.2.3 Japan
        1.2.4 China
        1.2.5 India
        1.2.6 Southeast Asia
    1.3 IBS-C Drugs Market by Type
        1.3.1 Linaclotide
        1.3.2 Lubiprostone
        1.3.3 Osmotic Laxatives
        1.3.4 Stimulant Laxatives
        1.3.5 Other
    1.4 IBS-C Drugs Market by End Users/Application
        1.4.1 Hospital Pharmacies
        1.4.2 Retail Pharmacies
        1.4.3 Online Pharmacies

2 Global IBS-C Drugs Competition Analysis by Players
    2.1 IBS-C Drugs Market Size (Value) by Players (2016 and 2017)
    2.2 Competitive Status and Trend
        2.2.1 Market Concentration Rate
        2.2.2 Product/Service Differences
        2.2.3 New Entrants
        2.2.4 The Technology Trends in Future

3 Company (Top Players) Profiles
    3.1 Catalent Pharmaceuticals Solutions
        3.1.1 Company Profile
        3.1.2 Main Business/Business Overview
        3.1.3 Products, Services and Solutions
        3.1.4 IBS-C Drugs Revenue (Value) (2012-2017)
        3.1.5 Recent Developments
    3.2 Nestle
        3.2.1 Company Profile
        3.2.2 Main Business/Business Overview
        3.2.3 Products, Services and Solutions
        3.2.4 IBS-C Drugs Revenue (Value) (2012-2017)
        3.2.5 Recent Developments
    3.3 Abbott Laboratories
        3.3.1 Company Profile
        3.3.2 Main Business/Business Overview
        3.3.3 Products, Services and Solutions
        3.3.4 IBS-C Drugs Revenue (Value) (2012-2017)
        3.3.5 Recent Developments
    3.4 Synergy Pharmaceuticals
        3.4.1 Company Profile
        3.4.2 Main Business/Business Overview
        3.4.3 Products, Services and Solutions
        3.4.4 IBS-C Drugs Revenue (Value) (2012-2017)
        3.4.5 Recent Developments
    3.5 Sucampo Pharmaceuticals
        3.5.1 Company Profile
        3.5.2 Main Business/Business Overview
        3.5.3 Products, Services and Solutions
        3.5.4 IBS-C Drugs Revenue (Value) (2012-2017)
        3.5.5 Recent Developments
    3.6 Novartis Pharma Ag
        3.6.1 Company Profile
        3.6.2 Main Business/Business Overview
        3.6.3 Products, Services and Solutions
        3.6.4 IBS-C Drugs Revenue (Value) (2012-2017)
        3.6.5 Recent Developments
    3.7 Astellas Pharmaceuticals
        3.7.1 Company Profile
        3.7.2 Main Business/Business Overview
        3.7.3 Products, Services and Solutions
        3.7.4 IBS-C Drugs Revenue (Value) (2012-2017)
        3.7.5 Recent Developments
    3.8 Ardelyx, Inc
        3.8.1 Company Profile
        3.8.2 Main Business/Business Overview
        3.8.3 Products, Services and Solutions
        3.8.4 IBS-C Drugs Revenue (Value) (2012-2017)
        3.8.5 Recent Developments
    3.9 Synthetic Biologics, Inc
        3.9.1 Company Profile
        3.9.2 Main Business/Business Overview
        3.9.3 Products, Services and Solutions
        3.9.4 IBS-C Drugs Revenue (Value) (2012-2017)
        3.9.5 Recent Developments
    3.10 Teva Pharmaceutical Industries
        3.10.1 Company Profile
        3.10.2 Main Business/Business Overview
        3.10.3 Products, Services and Solutions
        3.10.4 IBS-C Drugs Revenue (Value) (2012-2017)
        3.10.5 Recent Developments
    3.11 Bama-Geve, SLU
    3.12 Ferring BV
    3.13 Ironwood Pharmaceuticals, Inc
    3.14 Salix Pharmaceuticals Ltd
    3.15 Norgine B.V
    3.16 Prometheus Laboratories Inc
    3.17 Actavis Nordic A/S
    3.18 Albireo Pharma Inc
    3.19 Yuhan Corp
    3.20 Astrazeneca Plc
    3.21 The Menarini Group
    3.22 Ono Pharmaceutical Co., Ltd

4 Global IBS-C Drugs Market Size by Type and Application (2012-2017)
    4.1 Global IBS-C Drugs Market Size by Type (2012-2017)
    4.2 Global IBS-C Drugs Market Size by Application (2012-2017)
    4.3 Potential Application of IBS-C Drugs in Future
    4.4 Top Consumer/End Users of IBS-C Drugs

5 United States IBS-C Drugs Development Status and Outlook
    5.1 United States IBS-C Drugs Market Size (2012-2017)
    5.2 United States IBS-C Drugs Market Size and Market Share by Players (2016 and 2017)

6 EU IBS-C Drugs Development Status and Outlook
    6.1 EU IBS-C Drugs Market Size (2012-2017)
    6.2 EU IBS-C Drugs Market Size and Market Share by Players (2016 and 2017)

7 Japan IBS-C Drugs Development Status and Outlook
    7.1 Japan IBS-C Drugs Market Size (2012-2017)
    7.2 Japan IBS-C Drugs Market Size and Market Share by Players (2016 and 2017)

8 China IBS-C Drugs Development Status and Outlook
    8.1 China IBS-C Drugs Market Size (2012-2017)
    8.2 China IBS-C Drugs Market Size and Market Share by Players (2016 and 2017)

9 India IBS-C Drugs Development Status and Outlook
    9.1 India IBS-C Drugs Market Size (2012-2017)
    9.2 India IBS-C Drugs Market Size and Market Share by Players (2016 and 2017)

10 Southeast Asia IBS-C Drugs Development Status and Outlook
    10.1 Southeast Asia IBS-C Drugs Market Size (2012-2017)
    10.2 Southeast Asia IBS-C Drugs Market Size and Market Share by Players (2016 and 2017)

11 Market Forecast by Regions, Type and Application (2017-2022)
    11.1 Global IBS-C Drugs Market Size (Value) by Regions (2017-2022)
        11.1.1 United States IBS-C Drugs Revenue and Growth Rate (2017-2022)
        11.1.2 EU IBS-C Drugs Revenue and Growth Rate (2017-2022)
        11.1.3 Japan IBS-C Drugs Revenue and Growth Rate (2017-2022)
        11.1.4 China IBS-C Drugs Revenue and Growth Rate (2017-2022)
        11.1.5 India IBS-C Drugs Revenue and Growth Rate (2017-2022)
        11.1.6 Southeast Asia IBS-C Drugs Revenue and Growth Rate (2017-2022)
    11.2 Global IBS-C Drugs Market Size (Value) by Type (2017-2022)
    11.3 Global IBS-C Drugs Market Size by Application (2017-2022)

12 IBS-C Drugs Market Dynamics
    12.1 IBS-C Drugs Market Opportunities
    12.2 IBS-C Drugs Challenge and Risk
        12.2.1 Competition from Opponents
        12.2.2 Downside Risks of Economy
    12.3 IBS-C Drugs Market Constraints and Threat
        12.3.1 Threat from Substitute
        12.3.2 Government Policy
        12.3.3 Technology Risks
    12.4 IBS-C Drugs Market Driving Force
        12.4.1 Growing Demand from Emerging Markets
        12.4.2 Potential Application

13 Market Effect Factors Analysis
    13.1 Technology Progress/Risk
        13.1.1 Substitutes
        13.1.2 Technology Progress in Related Industry
    13.2 Consumer Needs Trend/Customer Preference
    13.3 External Environmental Change
        13.3.1 Economic Fluctuations
        13.3.2 Other Risk Factors

14 Research Finding/Conclusion

15 Appendix
    Methodology
    Analyst Introduction
    Data Source